IceCure's Advanced Multiprobe Cryoablation Technology Receives Patent Approval in Japan
November 25, 2024 - 22:01
IceCure Medical Ltd. has announced that its next-generation multiprobe cryoablation technology has received a Notice of Allowance from Japan's Patent Office. This significant development marks a key milestone for the company's innovative approach to minimally invasive medical procedures.
The multiprobe cryoablation technology is designed to enhance the effectiveness and efficiency of cryoablation treatments, which are used to destroy abnormal tissues through extreme cold. This advancement is expected to provide physicians with improved tools for treating various medical conditions, potentially leading to better patient outcomes.
The approval from Japan's Patent Office underscores the technological advancements that IceCure is bringing to the field of cryoablation, positioning the company for growth in the competitive medical technology market.
MORE NEWS
June 16, 2026 - 03:33
The tenured engineers of 2026The MIT School of Engineering has announced the promotion of ten faculty members to tenured positions in 2026. The group includes Jacob Andreas, Zachary Cordero, Christina Delimitrou, Sili Deng,...
June 15, 2026 - 03:56
Some anglers praise forward-facing sonar, others say high-tech fishing ruins a day at the lakeBISMARCK, N.D. (AP) - Ah, the serenity of fishing. The quiet lapping of water against the boat, the patient wait for a bite, the simple connection with nature. But that peace is being disrupted by...
June 14, 2026 - 23:19
LASD board to consider budget, SRO contract, technology purchasesLUDINGTON - The Ludington Area School District Board of Education is scheduled to hold a public hearing on the proposed budget for the 2026-27 school year ahead of its regular meeting on Monday,...
June 14, 2026 - 09:41
Credo Technology Group Holding (CRDO) Is Up 21.2% After Earnings Beat And DustPhotonics DealCredo Technology Group Holding saw its stock surge 21.2% following the release of its fourth-quarter and full-year FY26 results, which topped analyst expectations. The company reported sales of...